According to The Korea Herald, Samsung BioLogics Co. Ltd. announced on July 10 that it had signed a 511 billion won agreement with Swiss pharmaceutical company Novartis to produce products for Novartis. The two companies signed a letter of intent in June last year, but this time they decided to increase their investment.
Samsung Bioepis Signs 511 Billion KRW Manufacturing Agreement with Novartis
Jul 10, 2023 19:36
CST Updated
19:36
Samsung Biologics
Biopharmaceutical R&D and Manufacturer
Novartis
Drug Development and Manufacturing